amino-hexyl-phosphonate | 170158-33-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: amino-hexyl-phosphonate
• CAS: 170158-33-5
• 化学式: C₆H₁₆NO₃P
• 分子量: 181.172
• InChiKey: MBMVCIISEFHVHN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11.0
• 可旋转键数：
  7.0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  72.55
• 氢给体数：
  2.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  4,4'-双甲氧基三苯甲基氯 、 amino-hexyl-phosphonate 在 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 吡啶 为溶剂， 以74%的产率得到
  参考文献：
  名称：

  Sobkowski, Michal; Stawinski, Jacek; Kraszewski, Adam, Collection of Czechoslovak Chemical Communications, 1996, vol. 61, p. S238 - S241

  摘要：

  DOI：
• 作为产物：
  描述：

  bis(6-aminohexyl) phosphonate 在 水 作用下， 以71%的产率得到amino-hexyl-phosphonate
  参考文献：
  名称：

  Sobkowski, Michal; Stawinski, Jacek; Kraszewski, Adam, Collection of Czechoslovak Chemical Communications, 1996, vol. 61, p. S238 - S241

  摘要：

  DOI：

文献信息

• Synthetic LTA mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections
  申请人：Universitätsklinikum Freiburg

  公开号：EP2500349A1

  公开（公告）日：2012-09-19

  The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.

  本发明涉及可用作治疗和/或预防细菌感染的疫苗成分的合成脂美酸（LTA）模拟物。
• RNA ANTAGONIST COMPOUNDS FOR THE MODULATION OF HER3
  申请人：Hedtjarn Maj

  公开号：US20080318894A1

  公开（公告）日：2008-12-25

  The invention relates to oligomer compounds (oligomers), which target HER3 mRNA in a cell, leading to reduced expression of HER3 and/or HER2 and/or EGFR. Reduction of HER3 and/or HER2 and/or EGFR expression is beneficial for a range of medical disorders, such hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of HER3 and/or HER2 and/or EGFR using said oligomers, including methods of treatment.
• COMPOUNDS FOR THE MODULATION OF BETA-CATENIN EXPRESSION
  申请人：Worm Jesper

  公开号：US20090005335A1

  公开（公告）日：2009-01-01

  The invention relates to oligomer compounds (oligomers), which target beta-catenin mRNA in a cell, leading to reduced expression of beta-catenin. Reduction of beta-catenin expression is beneficial for a range of medical disorders, such as hyperproliferative disorders, such as cancer. The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of beta-catenin using said oligomers, including methods of treatment.
• MICROMIRs
  申请人：Obad Susanna

  公开号：US20090143326A1

  公开（公告）日：2009-06-04

  The present invention relates to very short heavily modified oligonucleotides which target and inhibit microRNAs in vivo, and their use in medicaments and pharmaceutical compositions.
• LNA ANTAGONISTS TARGETING THE ANDROGEN RECEPTOR
  申请人：Worm Jesper

  公开号：US20090181916A1

  公开（公告）日：2009-07-16

  The invention relates to oligonucleotide compounds (oligomers), which target androgen receptor mRNA in a cell, leading to reduced expression of the androgen receptor. Reduction of androgen receptor expression is beneficial for the treatment of certain disorders, such as hyperproliferative disorders (e.g., cancer). The invention provides therapeutic compositions comprising oligomers and methods for modulating the expression of androgen receptor using said oligomers, including methods of treatment.